



Impact of environmental factors and physical activity on disability and quality of life in CIDP

Pietro Emiliano Doneddu¹ · Elisa Bianchi² · Dario Cocito³ · Fiore Manganelli⁴ · Raffaella Fazio⁵ · Massimiliano Filosto⁶ · Ettore Beghi² · Anna Mazzeo⁷ · Giuseppe Cosentino^{8,9} · Andrea Cortese^{8,9} · Stefano Jann¹⁰ · Angelo Maurizio Clerici¹¹ · Giovanni Antonini¹² · Gabriele Siciliano¹³ · Girolama Alessandra Marfia¹⁴ · Chiara Briani¹⁵ · Giuseppe Lauria^{16,17} · Tiziana Rosso¹⁸ · Guido Cavaletti¹⁹ · Marinella Carpo²⁰ · Luana Benedetti²¹ · Angelo Schenone²² · Giuseppe Liberatore¹ · Erdita Peci²³ · Emanuele Spina⁴ · Stefano Tronci⁵ · Stefano Cotti Piccinelli⁶ · Antonio Toscano⁷ · Luca Gentile⁷ · Laura Piccolo^{8,9} · Luca Leonardi¹² · Giorgia Mataluni¹⁴ · Marta Ruiz¹⁵ · Mario Sabatelli^{24,25} · Lucio Santoro⁴ · Eduardo Nobile-Orazio^{1,26} on behalf of the Italian CIDP Database Study Group

Received: 8 March 2020 / Revised: 11 May 2020 / Accepted: 13 May 2020 / Published online: 19 May 2020
© Springer-Verlag GmbH Germany, part of Springer Nature 2020

Abstract

A few observational studies and randomized trials suggest that exercise and rehabilitation may improve activity limitation and quality of life (QoL) in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), but the impact of other modifiable factors on the severity of the disease is not well understood. Using a structured questionnaire, we collected data on lifestyle and dietary habits of the patients included in the Italian CIDP database to investigate the possible influence of modifiable lifestyle factors on disability and QoL. Questionnaire data were available for 323 patients. The effect of lifestyle and dietary exposures on impairment, disability and QoL was evaluated using logistic regression models, adjusting for age, sex, disease duration, physical activity and smoking. Physical activity was associated with lower sensory impairment by the ISS scale, less disability by the INCAT and RODS scale and a better QoL in all the domains of EURO-QoL scale with the exception of anxiety/depression. None of the other parameters had an impact on these scales. This study adds evidence to the possible role of physical activity in improving symptom severity, disability and QoL in patients with CIDP. None of the other environmental factors investigated appeared to have an impact on the severity and health perception of CIDP.

Keywords Chronic inflammatory demyelinating polyradiculoneuropathy · CIDP · Physical activity · Epidemiology · Disability · Quality of life

Introduction

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated chronic neuropathy leading to a temporary or permanent disability in about 50% of the patients [1]. Several retrospective studies on large series of patients and a few randomized controlled trials have shown the efficacy of corticosteroids, plasma exchange, and intravenous immunoglobulin (IVIg) in CIDP [1]. However, only about 80% of patients respond to these therapies [1]. A possible influence of modifiable lifestyle components on

the progression of the disease has been reported in other immune-mediated diseases including multiple sclerosis and rheumatoid arthritis [2–11]. A possible role of physical activity or rehabilitation in reducing disability has been reported in patients with inflammatory neuropathies [12–21] (Table 1), while the contribution of other potentially modifiable factors has not been investigated. The identification of these modifiable environmental factors might form the basis of a secondary preventive approach to disease management. Recently, we found that consumption of rice and fish were associated with lower risk to develop CIDP [22]. We now investigated the association of some lifestyle and dietary habits with disability, symptom severity and QoL in patients with CIDP.

✉ Eduardo Nobile-Orazio
eduardo.nobile@unimi.it

Extended author information available on the last page of the article

Table 1 Previous studies evaluating the beneficial effect of physical activity or rehabilitation in inflammatory neuropathies

References	Participants	Design	Intervention	Outcome	Case no	Main finding
[20]	CIDP, Chronic neuropathies	Prospective randomized controlled trial	Home exercise program	AMS, grip strength, FVC, 30-ft walk, SF-36	21	Improvement in AMS and grip strength
[12]	GBS, CIDP	Observational study	12-week bicycle exercise training	FSS, RAM, FIS, GBS disability score, HADS, RHS, SF-36	40	Improvement in FSS, FIS, HADS, RHS, SF-36
[15]	GBS, CIDP	Observational study	12-week physical exercise program	VO ₂ peak, POpeak, FSS, AM, SF-36, FIS, RHS, HADS	20	Improvement in POpeak, VO ₂ peak, FSS, FIS, HADS, RHS
[13]	GBS, CIDP, and healthy controls	Observational study	12-week strengthening, aerobic and functional exercise program	ODSS, SF-36, HADS, FSS, cIKS	26	Improvement in ODSS, SF-36, HADS, FSS, cIKS
[14]	GBS in later stages of recovery	Single blind randomized controlled trial	High- vs low-intensity multidisciplinary ambulatory rehabilitation program over 12 months	FIM, WHOQoL-BREF, DASS, PIPP	69	More significant improvement in FIM and PIPP with higher intensity rehabilitation
[19]	GBS	Observational study	Comprehensive individually tailed rehabilitation	MRC, FIM, 6-MWT, 10-min walking test	45	Improvements in all outcome measures
[16]	GBS	Observational study	Inpatient rehabilitation	FIM	1079	Improvement in all the three domains of the FIM
[17]	CIDP	Controlled trial	Aerobic or resistance exercise training for 12 weeks, followed by the other training regimen	VO ₂ -max, cIKS, 6-MWT, ODSS, FSS, SF-36	17	Improvement in VO ₂ -max and cIKS
[18]	CIDP	Observational study	One-year follow-up after aerobic or resistance exercise training for 12 weeks, followed by the other training regimen	VO ₂ -ma, cIKS, 6-MWT, ODSS, FSS, SF-36, MRC	10	Patients that continued aerobic and resistance exercise preserved their cIKS and VO ₂ -max gains after one year of follow-up
[21]	GBS	Observational study	Inpatient rehabilitation	MRC, GBS disability score, ability to walk	40	Improvement in MRC, GBS disability score, and ability to walk

AM actual mobility, AMS average muscle score, CIDP chronic inflammatory demyelinating polyradiculoneuropathy, cIKS isokinetic muscle strength, DASS Depression Anxiety Stress Scale-21, FIM functional independence measure, FIS Fatigue Severity Scale, FSS Fatigue Severity Scale, ft feet, FVC forced vital capacity, GBS Guillain-Barré syndrome, HADS Hospital Anxiety And Depression Scale, MRC Medical Research Council, ODSS Overall Disability Sum Score, PIPP perceived impact problem profile, POpeak peak power output, QoL quality of life, RAM Rotterdam Activity Monitor, RHS Rotterdam Handicap Scale, SF-36 Short-Form 36, VO₂-max maximal oxygen consumption velocity, WHOQoL-BREF World Health Organization Quality of Life, 6-MWT 6-min-Walk Test

Materials and methods

Study design

We implemented a web-based database on Italian CIDP patients where, at present, data from 500 patients with a diagnosis of CIDP or one of its variants, followed by 22 Italian Centers with expertise in immune-mediated neuropathies, are included [23]. At enrollment, all eligible patients underwent a detailed clinical history including timing and distribution of neurological signs, a number of disability scales, and a QoL scale. We used the same methodology as the one employed in a previous study [23]. In this study, we collected information about lifestyle and dietary habits, related to the period after CIDP diagnosis, using a structured questionnaire. Inclusion criteria for this study were patients fulfilling the European Federation of Neurological Societies and Peripheral Nerve Society (EFNS/PNS) diagnostic criteria for CIDP [24]. Patients with a clinical diagnosis of CIDP not fulfilling the EFNS/PNS criteria were excluded, as were patients with an alternative diagnosis for the neuropathy or with increased titers of anti-MAG (myelin-associated glycoprotein) antibodies (over 7000 by Bühlman method) or without available nerve conduction studies. Only patients with an IgM monoclonal gammopathy were tested for anti-MAG antibodies. All the data were included by the treating neurologist in a web-based electronic database expressly prepared by CINECA, Bologna, Italy.

Assessment of lifestyle and dietary habits

We asked the patients for exposure to toxic agents (prolonged vs. never/occasionally), smoking (including duration and amount of exposure), illicit drug consumption (repeated vs. never/occasionally), regular alcohol use including amount of exposure (1–3 drinks per day, 4–6 drinks per day, 7–9 drinks per day, ≥ 10 drinks per day on average), regular physical activity (type [walking for at least 30 min, running, swimming, cycling, gymnastic, team sport, others to be specified] and frequency [< 1 time per week, 1 time per week, 2–3 times per week, > 3 times per week]), dietary regimen (vegan, vegetarian, macrobiotic, omnivorous, others to be specified), and frequency of consumption of a variety of foods (1 or more time per day, 3–4 times per week, 1–2 times per week, 2–3 times per month). Items related to dietary habits included pasta, rice, meat, raw meat, white meat, fish, vegetables, fruit, cheese, eggs, sweets, coffee, tea, milk, and soft drinks.

Assessment of impairment, disability, and quality of life

The clinical evaluation at enrollment included the following outcome measures: muscle strength measured by the

Medical Research Council (MRC) sum score on 12 muscles (ranging from 0—worst to 60—best); overall sensory function measured by the INCAT sensory scale (ISS) (range from 0—best to 20—worst); neurological disability evaluated at enrollment with the Inflammatory-Rash Overall Built Disability Scale (I-RODS) (range from 0—worst to 48—best) and the Inflammatory Neuropathy Cause and Treatment (INCAT) disability scale (range from 0—best to 10—worst); QoL was measured using the EUROQoL-5D-3L scale. The scale consists of five domains, each with a score from 1—best to 3—worst that measure different aspects of QoL: mobility, self-care, usual activities, pain, anxiety/depression); the EQ VAS (Euro-QoL visual analog scale) that records the patient's self-rated health on a vertical visual analog scale, where a score of 100 refers to the best imaginable health state and a score of 0 refers to the worst imaginable health state. The VAS can be used as a quantitative measure of health outcome that reflects the patient's own judgment.

Statistical analysis

Descriptive statistics were performed on the available exposure and outcome variables in the entire sample. Data were reported as frequencies and percentages for categorical variables and as medians and interquartile ranges for continuous variables. Since most of the patients performing physical activity in our cohort reported to walk while only a minority of them performed other sport activities, physical activity was analyzed considering separately walking and performing other sport activities. The effect of lifestyle and dietary exposures on impairment, disability and QoL was evaluated using logistic regression models. The four outcomes measuring impairment (MRC, ISS) and disability (INCAT, I-RODS) were analyzed separately. For each of the four outcome measures, patients were divided into two groups based on the median of the distribution of the outcome score: (1) from 0 to the median; (2) above the median. The association was then evaluated using logistic regression models. In each model, the outcome, categorized as described above, was the dependent variable, and exposures were the independent variables. The probability modeled was that of having a higher level of impairment (MRC, ISS) or disability (INCAT, I-RODS). All models were adjusted for age, sex, disease duration (years), physical activity (yes vs. no) and smoke (yes vs. no). Models with the two disability outcomes (INCAT, I-RODS) as dependent variables were also adjusted for impairment (MRC, ISS). The association of each exposure variable with each different domain of QoL (mobility, self-care, usual activities, pain, anxiety/depression) was evaluated using separate ordinal logistic regression models, with the QoL domain (categorized as 1, 2 or 3) as dependent variable, and exposures as independent variables. For the EQ VAS score, patients were divided into quartiles,

and ordinal logistic regression models, with EQ VAS quartiles as dependent variable and exposures as independent variables, were used to evaluate the impact of each exposure variable on the EQ VAS score. The probability modeled was that of having a good level of QoL. All models were adjusted for age, sex, disease duration (years), physical activity (yes vs. no) and smoking (yes vs. no). Results obtained from each logistic regression model were expressed as odds ratio (OR) with 95% confidence interval (CI). All tests were two-tailed and the significance level was set at 0.05. Statistical analyses were performed with the SAS statistical package, version 9.4 (SAS Institute, Cary, NC, USA).

Results

A total of 323 patients fulfilling the EFNS/PNS criteria for CIDP were included in the analysis. Of these patients, 214 (66%) were males and 109 (34%) were females, with an average age at study entry of 57 years (median 58 years; range 11–89 years) and mean disease duration of 8.5 years (median 6 years; range 0.5–52 years). The description of exposures and outcome variables in the study sample is reported in Table 2. Logistic regression models showed that patients performing physical activity had lower impairment measured by ISS and lower disability measured by INCAT and RODS, while no association was found with MRC (Table 3). Data for QoL were available for 315 patients. Performing any physical activity was associated with higher quality of life measured by the EQ VAS and in all the EURO-QoL domains, except for anxiety/depression (Table 4). None of the remaining exposure variables revealed significant associations. The predominant type of physical activity reported by the sample was walking. Among the 155 patients performing at least one type of physical activity, a total of 64 patients only walked, while 91 were involved in at least one sport activity. A stronger association with a lower disability measured by INCAT was observed for sport activities compared to walking alone, while a similar effect of the two types of physical activity was observed on I-RODS (Table 3). When considering the EQ VAS score and mobility, self-care and pain domains of QoL, the effect of physical activity was mainly driven by sport activities, while the effect of sports on usual activities domain was similar to walking (Table 4). A positive effect on anxiety/depression domain was observed for walking, but not for other sport activities (Table 4).

Discussion

In this study, physical activity was associated with lower sensory impairment, less disability and a better QoL. Although reverse causality may have contributed to the

Table 2 Descriptive statistics of exposure and outcome variables

Exposures	<i>n</i>	%
Exposure to toxic agents		
No	261	81.1
Yes	61	18.9
NA	1	
Physical activity		
No	168	52.0
Yes	155	48.0
Type of physical activity		
Walking	103	31.9
Running	10	3.1
Swimming	29	9.0
Cycling	34	10.5
Gym	34	10.5
Team sport	5	1.6
Other sport	12	3.7
Smoke		
No	166	51.4
Yes	157	48.6
Regular alcohol consumption		
No	204	63.2
Yes	119	36.8
Illegal substances consumption		
No	311	98.7
Yes	4	1.3
NA	8	
Dietary restrictions		
No	298	92.3
Yes	25	7.7
Dietary regimen		
Omnivorous	320	99.1
Vegetarian	3	0.9
Impairment	Median	IQR
MRC score	56	52–60
ISS score	4	2–8
Disability	Median	IQR
INCAT score	2	1–4
I-RODS score	35	26–42
EURO-QOL-5D-3L (<i>n</i> = 315)	<i>n</i>	%
Mobility		
1	86	27.3
2	221	70.2
3	8	2.5
Self-care		
1	194	61.6
2	111	35.2
3	10	3.2
Usual activities		
1	124	39.4
2	181	56.0
3	10	3.1

Table 2 (continued)

Exposures	<i>n</i>	%
Pain/discomfort		
1	137	43.5
2	168	53.3
3	10	3.2
Anxiety/depression		
1	156	49.6
2	145	46.0
3	14	4.4
EQ VAS (quartiles)		
1 (0–49)	51	17.4
2 (50–59)	62	21.1
3 (60–74)	106	36.0
4 (75–100)	75	25.5
NA	21	

INCAT Inflammatory Neuropathy Cause and Treatment disability scale, *IQR* interquartile range, *I-RODS* Inflammatory-Rash Overall Built Disability Scale, *ISS* INCAT sensory scale, *MRC* Medical Research Council, *EQ VAS* Euro-QoL visual analogue scale, *NA* not available

Table 3 Association of physical activity with impairment and disability

	OR	95% CI	<i>p</i> value
Any physical activity			
INCAT	0.58	0.35–0.99	0.0476
I-RODS	0.44	0.26–0.75	0.0023
MRC	1.28	0.82–2.00	0.2853
ISS	0.62	0.40–0.98	0.0421
Only walking			
INCAT	0.74	0.37–1.47	0.3933
I-RODS	0.47	0.23–0.78	0.0335
MRC	1.63	0.90–2.96	0.1098
ISS	0.58	0.31–1.05	0.0727
At least one sport activity			
INCAT	0.49	0.26–0.92	0.0267
I-RODS	0.41	0.22–0.78	0.0060
MRC	1.07	0.64–1.82	0.7852
ISS	0.66	0.39–1.13	0.1307

CI confidence interval, *INCAT* Inflammatory Neuropathy Cause and Treatment disability scale, *I-RODS* Inflammatory-Rash Overall Built Disability Scale, *ISS* INCAT sensory scale, *MRC* Medical Research Council, *OR* odds ratio

magnitude of the effect for disability, the association remained statistically significant after adjusting the model for the extent of impairment, suggesting that, at the same impairment level, patients who practice physical activity have less disability and better QoL.

Table 4 Association of physical activity with quality of life

	OR	95% CI	<i>p</i> value
Any physical activity			
Mobility	2.01	1.20–3.35	0.0073
Self-care	2.05	1.28–3.29	0.0030
Usual activities	2.17	1.37–3.45	0.0010
Pain	1.91	1.21–3.02	0.0053
Anxiety/depression	1.41	0.90–2.20	0.1316
EQ VAS (quartiles)	2.08	1.36–3.19	0.0008
Only walking			
Mobility	1.94	0.95–3.96	0.0673
Self-care	1.79	0.94–3.42	0.0787
Usual activities	2.62	1.39–4.95	0.0030
Pain	1.45	0.80–2.63	0.2260
Anxiety/depression	1.94	1.07–3.53	0.0298
EQ VAS (quartiles)	1.97	1.12–3.47	0.0183
At least one sport activity			
Mobility	2.57	1.37–4.81	0.0033
Self-care	3.23	1.69–6.20	0.0004
Usual activities	2.42	1.37–4.29	0.0025
Pain	2.45	1.41–4.26	0.0014
Anxiety/depression	1.14	0.67–1.93	0.6239
EQ VAS (quartiles)	2.31	1.39–3.83	0.0012

CI confidence interval, *OR* odds ratio, *EQ VAS* Euro-QoL visual analog scale

Ameliorative effect of physical activity on sensory symptoms has been observed in chemotherapy-induced [25, 26] and diabetic neuropathy [27–29], and a recent study showed that physical activity was associated with less sensory neuropathy symptoms and better sensory nerve action potential amplitudes in older men [30]. Potential mechanisms include the anti-inflammatory [31] and the regenerative effect on nerve fibers of physical exercise [26, 28, 29, 32]. Previous studies have not evaluated the impact of physical activity and rehabilitation on the sensory symptoms of patients with inflammatory neuropathies (Table 1).

Our findings are also in line with the results of three previous observational studies showing that supervised aerobic cycling [12, 15], or unsupervised physiotherapist-prescribed community-based aerobic and strengthening exercise [13], is associated with an improvement in disability, fatigue and QoL in people with inflammatory neuropathies. A randomized controlled trial evaluating home-based exercise in patients with different chronic neuropathies including CIDP found that muscle and grip strength improved significantly [20]. These findings were subsequently confirmed by a controlled trial and its 1-year follow-up study that showed that aerobic or resistance exercise training improved strength and aerobic capacity of CIDP patients [17, 18], even if disability, fatigue, and QoL did not improve [17, 18]. Since all

participants in this study were treated at home with subcutaneous immunoglobulin, it is possible that this has negatively affected QoL and fatigue [17]. Other explanations are that participants were more severely affected than in the previous interventional studies [12, 13] and training programs were not focused on the weakest muscle groups in each patient. In our study, physical activity was not supervised by health personnel in the context of a study, therefore it is possible that each patient chose the type of physical activity most appropriate for his/her disturbances and that this led to a greater impact on disability and QoL.

The mechanisms underlying the improvement of muscle strength following physical activity are unknown, but could be due to an anti-inflammatory effect of exercise on the nerve lesions or muscle fiber hypertrophy or increased neural drive [17]. Future studies should investigate these underlying mechanisms in more detail using electroneurography as well as nerve and muscle imaging.

Several studies have shown an association of diet, cigarette, alcohol consumption, and toxic agent exposure with the progression of disability and QoL in different autoimmune disorders [2–11]. We did not find an association between any of these environmental factors and the impairment, disability and QoL of patients with CIDP. One possible explanation is that the questionnaire used in our study was not able to capture the quality of diet by assessing intake of each food instead of estimating the overall dietary quality by using indicators of compliance with dietary recommendations. Future studies should evaluate the impact of diet in the progression of CIDP by using a specific questionnaire designed to capture healthy eating such as adherence to Mediterranean-style diet. We also did not find an association between rice and fish consumption and impairment and disability, suggesting that these dietary factors may influence the risk of CIDP, but not its severity [22].

The limitations of our study include the use of a non-validated lifestyle and dietary habit questionnaire. In addition, this was an observational cross-sectional retrospective study that cannot prove causality, but supports previous interventional studies showing that regular exercise may have an impact on disability and QoL in CIDP. It is also possible that CIDP patients that are severely disabled and impaired might not be able to perform physical activities and sport. Last, as this is not a population-based study, our findings might be affected by selection bias. Further epidemiological and intervention studies are needed to confirm our results in order to support a possible role of physical activity as part of a secondary preventive strategy.

Acknowledgements **Italian CIDP Database study group:** Pietro Emiliano Doneddu, Giuseppe Liberatore, Francesca Gallia, and Eduardo Nobile-Orazio from the Department of Medical Biotechnology and Translational Medicine, Neuromuscular and Neuroimmunology Service, Humanitas Clinical and Research Institute, Milan

University, Rozzano, Milan, Italy; Erdita Peci and Dario Cocito from the Department of Neuroscience, University of Turin, Turin, Italy. Daniele Velardo, Stefano Tronci and Raffaella Fazio from the Division of Neuroscience, Department of Neurology, Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute, Milan, Italy; Fiore Manganeli, Emanuele Spina, Antonietta Topa and Lucio Santoro from the Department of Neuroscience, Reproductive Sciences and Odontostomatology, University of Naples ‘Federico II’, Naples, Italy; Marta Ruiz and Chiara Briani from the Neurology Unit, Department of Neuroscience, University of Padua, Padua, Italy. Stefano Cotti Piccinelli, Alice Todeschini and Massimiliano Filosto from the Center for Neuromuscular Diseases and Neuropathies, Unit of Neurology ASST ‘Spedali Civili’, University of Brescia, Brescia, Italy; Corrado Cabona, Angela Zuppa and Luana Benedetti from the IRCCS Ospedale Policlinico San Martino, Genova, Italy; Antonio Toscano, Luca Gentile and Anna Mazzeo from the Department of Clinical and Experimental Medicine, Unit of Neurology, University of Messina, Messina, Italy; Giorgia Mataluni and Girolama Alessandra Marfia from the Disimmune Neuropathies Unit, Department of Systems Medicine, Tor Vergata University of Rome, Rome, Italy; Giuseppe Cosentino, Laura Piccolo, Iliaria Callegari and Andrea Cortese from the University of Pavia, IRCCS Foundation C. Mondino, Pavia, Italy; Verrengia Elena Pinuccia and Stefano Jann from the Department of Neuroscience, Niguarda Ca’ Granda Hospital, Milan, Italy; Elisa Bianchi and Ettore Beghi from the Laboratorio di Malattie Neurologiche, IRCCS-Istituto Mario Negri, Milan, Italy; Angelo Maurizio Clerici from the Neurology Unit, Circolo and Macchi Foundation Hospital, Insubria University, DBSV, Varese, Italy; Federica Scarscia and Marinella Carpo from the ASST Bergamo Ovest-Ospedale Treviglio, Treviglio, Italy; Martina Garnerò and Angelo Schenone from the Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa and IRCCS AOU San Martino-IST, Genoa, Italy; Marco Luigetti from Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOC Neurologia, Università Cattolica del Sacro Cuore, Roma, Italy; Mario Sabatelli from Centro Clinico NEMO Adulti, Università Cattolica del Sacro Cuore, Roma, Italy; Patrizia Dacci and Giuseppe Lauria from the Unit of Neuroalgology, IRCCS Foundation ‘Carlo Besta’ Neurological Institute, Milan, Italy; Luca Leonardi and Giovanni Antonini from the Unit of Neuromuscular Diseases, Department of Neurology Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, ‘Sapienza’ University of Rome, Sant’Andrea Hospital, Rome, Italy; Tiziana Rosso from the Azienda UL.SS. 8 Asolo, Castelfranco Veneto, Italy; Erika Schirinzi and Gabriele Siciliano from the Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; Claudia Balducci and Guido Cavaletti from the School of Medicine and Surgery and Experimental Neurology Unit, University of Milano-Bicocca, Monza, Italy.

Author contributions PED designed and conceptualized the study, had a major role in the acquisition of data, analyzed the data, and wrote the first draft of the manuscript. EBianchi designed and executed the statistical analysis, contributed to the conception, organization, and execution of the research project, and reviewed and commented on the statistical analysis and the report. DC, FM, RF, MF, EBeghi, AM, GC, AC, SJ, AMC, GA, GS, GAM, CB, GL, TR, GC, MC, LB, AS, GL, EP, ES, ST, SCP, AT, LG, LP, EPV, LL, ES, GM, MR, MS and LS contributed to the study conception and design, had a major role in acquisition and interpretation of data and revised the manuscript for intellectual content. ENO conceived, organized and designed the study, reviewed and commented on the statistical analysis and reviewed the report.

Funding The study was supported by a grant from Regione Lombardia, Italy, for patients from this region and subsequently extended to other Italian centers. The study was also supported by unrestricted grants

from Kedrion Biopharma (Italy), CSL Behring (Italy), Humanitas Clinical and Research Institute (Milan, Italy), and GBS-CIDP Foundation International (USA). The funders had no role in study design, data collection and analysis, decision to publish, or in the preparation of the manuscript.

Data availability The data that support the findings of this study are available from the corresponding author, upon request.

Compliance with ethical standards

Conflicts of interest Pietro Emiliano Doneddu has received travel grants to attend scientific meetings from CSL Behring and Kedrion. Dario Cocito has received honoraria for lecturing from Shire, CSL Behring, and Kedrion and travel grants to attend scientific meeting from Shire, Kedrion, and CSL Behring. Fiore Manganello reports personal fees for scientific events from CSL Behring and has received travel grants to attend scientific meetings from CSL Behring and Kedrion. Raffaella Fazio has served on scientific advisory boards for CSL Behring and has received travel grants from Kedrion and CSL Behring to attend scientific meeting. Chiara Briani has served on scientific advisory boards for Pfizer, Alnylam, and Akcea, and has received travel grants from Kedrion and CSL Behring to attend scientific meeting. Massimiliano Filosto has served on scientific advisory boards for CSL Behring and has received travel grants from Kedrion, Baxter and CSL Behring to attend scientific meeting. Stefano Jann has received research grants from Grifols, outside this work, and travel grants from Grifols and Kedrion. Anna Mazzeo has received travel grants from Kedrion and CSL Behring to attend scientific meeting. Giuseppe Cosentino has received travel grants to attend scientific meetings from CSL Behring and Kedrion. Andrea Cortese has received travel grants to attend scientific meetings from Kedrion. Marinella Carpo has received travel grants to attend scientific meetings from Kedrion. Guido Cavalletti has received honoraria for lecturing and travel grants to attend scientific meetings from Kedrion. Ettore Beghi reports grants from UCB-Pharma, grants from Shire, grants from EISAI, personal fees from Viropharma, grants from Italian Ministry of Health, grants from Fondazione Borgonovo, grants from Associazione IDIC 15 and grants from European Union, outside the submitted work. Giuseppe Liberatore has received travel grants to attend scientific meetings from CSL Behring and Kedrion. Lucio Santoro reports personal fees for scientific events from CSL Behring and has received travel grants to attend scientific meetings from CSL Behring and Kedrion. Erdita Peci has received travel grants to attend scientific meetings from CSL Behring. Eduardo Nobile Orazio reports personal fees for Advisory or Scientific Board from Kedrion, Italy, Baxter, Italy, Novartis, Switzerland, CSL-Behring, Italy, Astellas, the Netherlands, outside the submitted work and travel grants to attend Scientific Meeting from Baxter, Grifols, Kedrion, and Novartis, Italy. The other authors declare no conflict of interest.

Ethics approval The study was approved by the Ethical Committee of each participating center.

Consent to participate Written informed consent was obtained from all participants at enrollment.

References

- Nobile-Orazio E (2014) Chronic Inflammatory demyelinating polyradiculoneuropathy. Where we are, where we should go. *J Peripher Nerv Syst* 19:2–13. <https://doi.org/10.1111/jns5.12053>
- Jelinek GA, De Livera AM, Marck CH, Brown CR, Neate SL, Taylor KL et al (2016) Associations of lifestyle, medication, and socio-demographic factors with disability in people with multiple sclerosis: an international cross-sectional study. *PLoS ONE* 25(11):e0161701. <https://doi.org/10.1371/journal.pone.0161701>
- Belbasis L, Bellou V, Evangelou E, Ioannidis JPA, Tzoulaki I (2015) Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. *Lancet Neurol* 14:263–273. [https://doi.org/10.1016/S1474-4422\(14\)70267-4](https://doi.org/10.1016/S1474-4422(14)70267-4)
- Manzel A, Muller DN, Hafler DA, Erdman SE, Linker RA, Kleiweietfeld M (2014) Role of “Western Diet” in inflammatory autoimmune diseases. *Curr Allergy Asthma Rep* 14:404. <https://doi.org/10.1007/s11882-013-0404-6>
- Fitzgerald KC, Tyry T, Salter A, Cofield SS, Cutter G, Fox R et al (2018) Diet quality is associated with disability and symptom severity in multiple sclerosis. *Neurology* 90:1–11. <https://doi.org/10.1212/WNL.0000000000004768>
- Harel-Meir M, Sherer Y, Shoenfeld Y (2007) Tobacco smoking and autoimmune rheumatic diseases. *Nat Clin Pract Rheumatol* 3:707–715. <https://doi.org/10.1038/ncprheum0655>
- Weiland TJ, Hadgkiss EJ, Jelinek GA, Pereira NG, Marck CH, van der Meer DM (2014) The association of alcohol consumption and smoking with quality of life, disability and disease activity in an international sample of people with multiple sclerosis. *J Neurol Sci* 336:211–219. <https://doi.org/10.1016/j.jns.2013.10.046>
- Bombardier CH, Blake KD, Ehde DM, Gibbons LE, Moore D, Kraft GH (2004) Alcohol and drug abuse among persons with multiple sclerosis. *Mult Scler* 10:35–40. <https://doi.org/10.1191/1352458504ms9890a>
- Beier M, D’Orio V, Spat J, Shuman M, Foley FW (2014) Alcohol and substance use in multiple sclerosis. *J Neurol Sci* 338:122–127. <https://doi.org/10.1016/j.jns.2013.12.029>
- Swanson GR, Sedghi S, Farhadi A, Keshavarzian A (2010) Pattern of alcohol consumption and its effect on gastrointestinal symptoms in inflammatory bowel disease. *Alcohol* 44:223–228. <https://doi.org/10.1016/j.alcohol.2009.10.019>
- Stejskal J, Stejskal VD (1999) The role of metals in autoimmunity and the link to neuroendocrinology. *Neuro Endocrinol Lett* 20:351–364
- Garssen MP, Bussmann JB, Schmitz PI, Zandbergen A, Welter TG, Merkies IS et al (2004) Physical training and fatigue, fitness, and quality of life in Guillain-Barré syndrome and CIDP. *Neurology* 63:2393–2395. <https://doi.org/10.1212/01.WNL.0000148589.87107.9C>
- Graham RC, Hughes RA, White CM (2007) A prospective study of physiotherapist prescribed community based exercise in inflammatory peripheral neuropathy. *J Neurol* 254:228–235. <https://doi.org/10.1007/s00415-006-0335-4>
- Khan F, Pallant JF, Amatya B, Ng L, Gorelik A, Brand C (2011) Outcomes of high- and low-intensity rehabilitation programme for persons in chronic phase after Guillain-Barré syndrome: a randomized controlled trial. *J Rehabil Med* 43:638–646
- Bussmann JB, Garssen MP, van Doorn PA, Stam HJ (2007) Analysing the favourable effects of physical exercise: relationships between physical fitness, fatigue and functioning in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. *J Rehabil Med* 39:121–125
- Andrews AW, Middleton A (2018) Improvement during inpatient rehabilitation among older adults with Guillain-Barré syndrome, multiple sclerosis, Parkinson disease, and stroke. *Am J Phys Med Rehabil* 97:879–884
- Markvardsen LH, Overgaard K, Heje K, Sindrup SH, Christiansen I, Vissing J et al (2018) Resistance training and aerobic training improve muscle strength and aerobic capacity in chronic

- inflammatory demyelinating polyneuropathy. *Muscle Nerve* 57:70–76. <https://doi.org/10.1002/mus.25652>
18. Markvardsen LK, Carstens AR, Knak KL, Overgaard K, Vissing J, Andersen H (2019) Muscle strength and aerobic capacity in patients with CIDP one year after participation in an exercise trial. *J Neuromuscul Dis* 6:93–97
 19. Novak P, Šmid S, Vidmar G (2017) Rehabilitation of Guillain-Barré syndrome patients: an observational study. *Int J Rehabil Res* 40:158–163
 20. Ruhland JL, Shields RK (1997) The effects of a home exercise program on impairment and health-related quality of life in persons with chronic peripheral neuropathies. *Phys Ther* 77:1026–1039
 21. Prada V, Massa F, Salerno A, Fregosi D, Beronio A, Serrati C et al (2020) Importance of intensive and prolonged rehabilitative treatment on the Guillain-Barré syndrome long-term outcome: a retrospective study. *Neurol Sci* 41:321–327
 22. Doneddu PE, Bianchi E, Cocito D, Manganelli F, Fazio R, Filosto M et al (2020) Risk factors for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): antecedent events, lifestyle and dietary habits. Data from the Italian CIDP Database. *Eur J Neurol* 27:136–143. <https://doi.org/10.1111/ene.14044>
 23. Doneddu PE, Cocito D, Manganelli F, Fazio R, Briani C, Filosto M et al (2019) Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database. *J Neurol Neurosurg Psychiatry* 90:125–132. <https://doi.org/10.1136/jnnp-2018-318714>
 24. Joint Task Force of the EFNS and the PNS (2010) European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society First Revision. *J Peripher Nerv Syst* 15:1–9. <https://doi.org/10.1111/j.1529-8027.2010.00245.x>
 25. Zimmer P, Trebing S, Timmers-Trebing U, Schenk A, Paust R, Bloch W et al (2018) Eight-week, multimodal exercise counteracts a progress of chemotherapy-induced peripheral neuropathy and improves balance and strength in metastasized colorectal cancer patients: a randomized controlled trial. *Support Care Cancer* 26:615–624. <https://doi.org/10.1007/s00520-017-3875-5>
 26. Streckmann F, Lehmann HC, Balke M, Schenk A, Oberste M, Heller A et al (2018) Sensorimotor training and whole-body vibration training have the potential to reduce motor and sensory symptoms of chemotherapy-induced peripheral neuropathy—a randomized controlled pilot trial. *Support Care Cancer* 27:2471–2478. <https://doi.org/10.1007/s00520-018-4531-4>
 27. Gu Y, Dennis SM, Kiernan MC, Harmer AR (2018) Aerobic exercise training may improve nerve function in type 2 diabetes and pre-diabetes: a systematic review. *Diabetes Metab Res Rev* 35:e3099. <https://doi.org/10.1002/dmrr.3099>
 28. Cooper MA, Kluding PM, Wright DE (2016) Emerging relationships between exercise, sensory nerves, and neuropathic pain. *Front Neurosci* 10:372. <https://doi.org/10.3389/fnins.2016.00372>
 29. Kluding PM, Pasnoor M, Singh R, Jernigan S, Farmer K, Rucker J et al (2012) The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy. *J Diabet Complicat* 26:424–429. <https://doi.org/10.1016/j.jdiacom.2012.05.007>
 30. Lange-Maia BS, Cauley JA, Newman AB, Boudreau RM, Jakicic JM, Glynn NW et al (2016) Sensorimotor peripheral nerve function and physical activity in older men. *J Aging Phys Act* 24:559–566. <https://doi.org/10.1123/japa.2015-0207>
 31. Sharif K, Watad A, Bragazzi NL, Lichtbroun M, Amital H, Shoenfeld Y (2018) Physical activity and autoimmune diseases: get moving and manage the disease. *Autoimmun Rev* 17:53–72. <https://doi.org/10.1016/j.autrev.2017.11.010>
 32. Feter N, Freitas MP, Gonzales NG, Umpierre D, Cardoso RK, Rombaldi AJ (2018) Effects of physical exercise on myelin sheath regeneration: a systematic review and meta-analysis. *Sci Sports* 33:8–21. <https://doi.org/10.1016/j.scispo.2017.06.009>

Affiliations

Pietro Emiliano Doneddu¹ · Elisa Bianchi² · Dario Cocito³ · Fiore Manganelli⁴ · Raffaella Fazio⁵ · Massimiliano Filosto⁶ · Ettore Beghi² · Anna Mazzeo⁷ · Giuseppe Cosentino^{8,9} · Andrea Cortese^{8,9} · Stefano Jann¹⁰ · Angelo Maurizio Clerici¹¹ · Giovanni Antonini¹² · Gabriele Siciliano¹³ · Girolama Alessandra Marfia¹⁴ · Chiara Briani¹⁵ · Giuseppe Lauria^{16,17} · Tiziana Rosso¹⁸ · Guido Cavaletti¹⁹ · Marinella Carpo²⁰ · Luana Benedetti²¹ · Angelo Schenone²² · Giuseppe Liberatore¹ · Erdita Peci²³ · Emanuele Spina⁴ · Stefano Tronci⁵ · Stefano Cotti Piccinelli⁶ · Antonio Toscano⁷ · Luca Gentile⁷ · Laura Piccolo^{8,9} · Luca Leonardi¹² · Giorgia Mataluni¹⁴ · Marta Ruiz¹⁵ · Mario Sabatelli^{24,25} · Lucio Santoro⁴ · Eduardo Nobile-Orazio^{1,26} on behalf of the Italian CIDP Database Study Group

¹ Neuromuscular and Neuroimmunology Service, Humanitas Clinical and Research Center-IRCCS, Rozzano, Milan, Italy

² Laboratorio di Malattie Neurologiche, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy

³ Istituti Clinici Scientifici Maugeri, Turin, Italy

⁴ Department of Neuroscience, Reproductive Sciences and Odontostomatology, University of Naples ‘Federico II’, Naples, Italy

⁵ Division of Neuroscience, Department of Neurology, Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute, Milan, Italy

⁶ Center for Neuromuscular Diseases and Neuropathies, Unit of Neurology, ASST ‘Spedali Civili’, University of Brescia, Brescia, Italy

⁷ Department of Clinical and Experimental Medicine, Unit of Neurology, University of Messina, Messina, Italy

⁸ University of Pavia, Pavia, Italy

⁹ IRCCS Mondino Foundation, Pavia, Italy

¹⁰ Department of Neuroscience, Niguarda Ca’ Granda Hospital, Milan, Italy

¹¹ Neurology Unit, Circolo and Macchi Foundation Hospital, DBSV, Insubria University, Varese, Italy

- ¹² Department of Neurology Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Unit of Neuromuscular Diseases, 'Sapienza' University of Rome, Sant'Andrea Hospital, Rome, Italy
- ¹³ Department of Clinical and Experimental Medicine, Neurology Unit, University of Pisa, Pisa, Italy
- ¹⁴ Department of Systems Medicine, Dysimmune Neuropathies Unit, Tor Vergata University of Rome, Rome, Italy
- ¹⁵ Department of Neuroscience, Neurology Unit, University of Padua, Padua, Italy
- ¹⁶ Unit of Neuroalgology, IRCCS Foundation 'Carlo Besta' Neurological Institute, Milan, Italy
- ¹⁷ Department of Biomedical and Clinical Sciences 'Luigi Sacco', University of Milan, Milan, Italy
- ¹⁸ ULSS2 Marca Trevigiana, UOC Neurologia-Castelfranco Veneto, Treviso, Italy
- ¹⁹ School of Medicine and Surgery and Experimental Neurology Unit, University of Milano-Bicocca, Monza, Italy
- ²⁰ ASST Bergamo Ovest-Ospedale Treviglio, Treviglio, Italy
- ²¹ IRCCS Ospedale Policlinico San Martino Genova, Genoa, Italy
- ²² Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa and IRCCS AOU San Martino-IST, Genoa, Italy
- ²³ Department of Neuroscience, University of Turin, Turin, Italy
- ²⁴ Università Cattolica del Sacro Cuore. Sede di Roma, Rome, Italy
- ²⁵ Centro Clinico NEMO Adulti, Rome, Italy
- ²⁶ Department of Medical Biotechnology and Translational Medicine (BIOMETRA), Milan University, Milan, Italy